Drug shortages or anticipated issues with HIV drugs haven’t been recognized.
The US Meals and Drug Administration (FDA) is intently monitoring the drug provide chain because the COVID-19 pandemic has the potential to disrupt the provision of medical and pharmaceutical merchandise in the US.
The Nationwide Alliance of State and Territorial AIDS Administrators (NASTAD) has additionally remained involved with the foremost producers of HIV drugs as many of those merchandise depend on components produced in different nations.
As of July 7, 2020, there have been no reviews of producing issues or provide shortages of ART or PrEP.
Study extra about the FDA’s response to COVID-19exterior icon.